| Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma (NCT01608594) | Diwakar Davar | 2013-05-21 |
| A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma (NCT04567706) | Ohio State University Comprehensive Cancer Center | 2013-05-07 |
| Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (NCT01846143) | Craig L Slingluff, Jr | 2013-05-01 |
| Utility of Novel BRAF Test for Melanoma (NCT01840527) | Massachusetts General Hospital | 2013-05-01 |
| Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma (NCT01827111) | M.D. Anderson Cancer Center | 2013-04-25 |
| Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases (NCT01781026) | Yale University | 2013-04-01 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (NCT01829971) | Mirna Therapeutics, Inc. | 2013-04-01 |
| Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma (NCT01859845) | Northwestern University | 2013-04-01 |
| Second Echelon Node Study With Methylene Blue (NCT01823172) | Mayo Clinic | 2013-04-01 |
| The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma (NCT01813214) | Georgetown University | 2013-03-01 |
| Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (NCT01709162) | Bristol-Myers Squibb | 2013-03-01 |
| Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR (NCT02043184) | Michigan State University | 2013-03-01 |
| Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (NCT01740297) | Amgen | 2013-02-07 |
| In Vivo Real-time Detection of Circulating Melanoma Cells (NCT01776905) | University of Arkansas | 2013-02-01 |
| IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma (NCT01409174) | M.D. Anderson Cancer Center | 2013-02-01 |
| Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study (NCT01760499) | H. Lee Moffitt Cancer Center and Research Institute | 2013-01-24 |
| Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (NCT01682083) | Novartis Pharmaceuticals | 2013-01-08 |
| Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy (NCT01777802) | Mayo Clinic | 2013-01-02 |
| Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma (NCT01754376) | Massachusetts General Hospital | 2013-01-01 |
| Doxycycline, Temozolomide and Ipilimumab in Melanoma (NCT01590082) | M.D. Anderson Cancer Center | 2012-11-01 |
| Post-Approval Study of MelaFind (NCT01700114) | MELA Sciences, Inc. | 2012-11-01 |
| Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (NCT01711684) | Rockefeller University | 2012-10-16 |
| CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (NCT01740401) | Icahn School of Medicine at Mount Sinai | 2012-10-01 |
| A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (NCT01585350) | Craig L Slingluff, Jr | 2012-10-01 |
| Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (NCT01681212) | Bristol-Myers Squibb | 2012-10-01 |
| Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells (NCT01783431) | Medical University of South Carolina | 2012-10-01 |
| Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (NCT01673854) | Bristol-Myers Squibb | 2012-09-13 |
| Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation (NCT01682213) | Memorial Sloan Kettering Cancer Center | 2012-09-01 |
| A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma (NCT01672450) | University of Utah | 2012-09-01 |
| Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases (NCT02662725) | University Hospital, Lille | 2012-09-01 |
| The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma (NCT01677975) | Rigshospitalet, Denmark | 2012-09-01 |
| An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor (NCT01619774) | M.D. Anderson Cancer Center | 2012-09-01 |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas (NCT01625351) | St. Jude Children's Research Hospital | 2012-08-20 |
| Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions (NCT01568996) | John Kirkwood | 2012-08-01 |
| A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma (NCT01782508) | Peking University Cancer Hospital & Institute | 2012-08-01 |
| Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (NCT01565837) | Wolfram Samlowski | 2012-08-01 |
| Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel (NCT01666418) | University of Zurich | 2012-08-01 |
| Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (NCT01657591) | H. Lee Moffitt Cancer Center and Research Institute | 2012-07-27 |
| Collecting Solid Tumor Tissue to Identify New Treatments (NCT01658917) | National Cancer Institute (NCI) | 2012-07-24 |
| CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) (NCT01636882) | Viralytics | 2012-07-03 |
| Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) (NCT01584115) | Instituto de Investigação em Imunologia | 2012-07-01 |
| EF5 in Melanoma Patients (NCT01752257) | Douglas Tyler | 2012-07-01 |
| A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients (NCT01638676) | University of Louisville | 2012-07-01 |
| Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma (NCT01611675) | Massachusetts General Hospital | 2012-07-01 |
| Transfer of Genetically Engineered Lymphocytes in Melanoma Patients (NCT01586403) | Loyola University | 2012-07-01 |
| Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (NCT01597908) | Novartis Pharmaceuticals | 2012-06-04 |
| RBL001/RBL002 Phase I Clinical Trial (NCT01684241) | BioNTech RNA Pharmaceuticals GmbH | 2012-06-01 |
| Multiple Antigen-Engineered DC Vaccine for Melanoma (NCT01622933) | Lisa H. Butterfield, Ph.D. | 2012-06-01 |
| Minimally Invasive Groin Dissection for Melanoma (NCT01500304) | Mayo Clinic | 2012-06-01 |
| Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma (NCT01764009) | Valerio Therapeutics | 2012-06-01 |
| A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma (NCT01584648) | Novartis Pharmaceuticals | 2012-05-04 |
| Assessing the Patient Experience in Cancer Care (NCT01621295) | Mayo Clinic | 2012-05-01 |
| A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer (NCT01935453) | OrienGene Biotechnology Ltd. | 2012-05-01 |
| Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma (NCT01573494) | Centre Hospitalier Universitaire de Nice | 2012-05-01 |
| Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (NCT01546571) | Polynoma LLC | 2012-05-01 |
| PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy (NCT01666353) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-04-16 |
| A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (NCT01604889) | Incyte Corporation | 2012-03-29 |
| Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass (NCT01433302) | M.D. Anderson Cancer Center | 2012-03-01 |
| Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program (NCT01772771) | M.D. Anderson Cancer Center | 2012-03-01 |
| Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab (NCT01515189) | Bristol-Myers Squibb | 2012-02-17 |
| Trial of pIL-12 Electroporation Malignant Melanoma (NCT01502293) | OncoSec Medical Incorporated | 2012-02-14 |
| Positron Emission Tomography/Magnetic Resonance Imaging in Patients (NCT01557881) | Case Comprehensive Cancer Center | 2012-02-01 |
| Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved? (NCT01770002) | University of California, Davis | 2012-01-01 |
| Study of Anti-telomerase T CD4 Immunity in Melanoma (NCT02838433) | Centre Hospitalier Universitaire de Besancon | 2012-01-01 |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (NCT01351103) | Novartis Pharmaceuticals | 2011-12-01 |
| Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma (NCT01489059) | Bristol-Myers Squibb | 2011-12-01 |
| Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma (NCT01321437) | University of California, Irvine | 2011-12-01 |
| Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (NCT01400451) | Bristol-Myers Squibb | 2011-11-01 |
| Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation (NCT01474551) | Memorial Sloan Kettering Cancer Center | 2011-11-01 |
| Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma (NCT01435369) | Medivation, Inc. | 2011-11-01 |
| Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (NCT01437605) | H. Lee Moffitt Cancer Center and Research Institute | 2011-10-11 |
| Does the Aid of MelaFind Affect Clinical Management Decisions (NCT01387581) | MELA Sciences, Inc. | 2011-10-01 |
| IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma (NCT01409187) | M.D. Anderson Cancer Center | 2011-10-01 |
| Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma (NCT01425008) | Millennium Pharmaceuticals, Inc. | 2011-09-15 |
| A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination (NCT01432860) | Northwestern University | 2011-09-01 |
| Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma (NCT01435499) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-09-01 |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma (NCT01551693) | Dana-Farber Cancer Institute | 2011-09-01 |
| Videoscopic Ilioinguinal Lymphadenectomy for Melanoma (NCT02508909) | Istituto Oncologico Veneto IRCCS | 2011-09-01 |
| Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma (NCT01397708) | Alaunos Therapeutics | 2011-08-01 |
| Set-back Suture Versus Traditional Vertical Mattress Suture (NCT01773447) | University of California, Davis | 2011-08-01 |
| Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy (NCT01586767) | Massachusetts General Hospital | 2011-07-12 |
| Safety Study of MGA271 in Refractory Cancer (NCT01391143) | MacroGenics | 2011-07-01 |
| An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. (NCT01386580) | BBB-Therapeutics B.V. | 2011-07-01 |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT01366144) | National Cancer Institute (NCI) | 2011-06-20 |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma (NCT01350401) | Adaptimmune | 2011-06-01 |
| Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (NCT01425749) | Craig L Slingluff, Jr | 2011-06-01 |
| Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma (NCT02442466) | MelCure SA | 2011-05-01 |
| Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT01390818) | EMD Serono | 2011-05-01 |
| Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients (NCT01336270) | Assistance Publique - Hôpitaux de Paris | 2011-05-01 |
| Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal (NCT01341496) | National Cancer Institute (NCI) | 2011-04-18 |
| Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis (NCT01556503) | OHSU Knight Cancer Institute | 2011-04-01 |
| HYPAZ: Hypertension Induced by Pazopanib (NCT01392352) | Cambridge University Hospitals NHS Foundation Trust | 2011-04-01 |
| Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads (NCT01336985) | National Institutes of Health Clinical Center (CC) | 2011-03-28 |
| Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum (NCT01313429) | National Cancer Institute (NCI) | 2011-03-04 |
| Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma (NCT01092728) | M.D. Anderson Cancer Center | 2011-03-01 |
| Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma (NCT01531608) | University of Virginia | 2011-03-01 |
| Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer (NCT01355562) | Loma Linda University | 2011-03-01 |
| High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (NCT01266603) | M.D. Anderson Cancer Center | 2011-02-22 |
| Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel (NCT01272609) | Centre Hospitalier Universitaire de Nice | 2011-02-16 |
| Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients (NCT02285413) | Radboud University Medical Center | 2011-02-01 |